title: The anticancer effect of 2'-3'-dehydrosalannol on triple-negative breast cancer cells.
abstract: BACKGROUND
  Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast tumors and these breast tumors are usually aggressive and highly metastatic. Unfortunately, treatment options for TNBCs are limited; we have identified a novel molecule, 2'-3'-dehydrosalannol (DHS) and in this study we investigated the anticancer effect of DHS against TNBC cells.
  
  
  METHODS
  TNBC (MDA-MB 231; MDA-MB 468) cells were treated with DHS and its effect on cell viability, apoptosis and molecular mechanisms were analyzed.
  
  
  RESULTS
  DHS inhibited growth and induced apoptosis in TNBC cell lines. Molecular analysis suggested that DHS inhibited cathepsin-mediated pro-survival signaling [pAKT: phosphorylated protein kinase B; BCL-2: B-cell lymphoma 2 and cyclin D1] and induced pro-apoptotic markers such as BAX [BCL-2-associated X protein] and cleaved caspase-3.
  
  
  CONCLUSIONS
  Our results demonstrate that DHS inhibits cathepsin-mediated pro-survival signaling which resulted in growth arrest of TNBC cells. These findings suggest that DHS may be a promising agent for the prevention and treatment of TNBC.
authors: Center of Excellence in Cancer Research, Department of Biomedical Sciences, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA.
authors: Thiyagarajan
authors: T
authors: Boopalan
authors: Arunkumar
authors: A
authors: Arumugam
authors: Chendil
authors: C
authors: Damodaran
authors: Lakshmanaswamy
authors: L
authors: Rajkumar
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D051017:Apoptosis Regulatory Proteins / Q000096:biosynthesis; D031601:Azadirachta / Q000737:chemistry; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D048708:Cell Growth Processes / Q000187:drug effects; D045744:Cell Line, Tumor; D015536:Down-Regulation / Q000187:drug effects; D005260:Female; D006576:Heterocyclic Compounds, 4 or More Rings / Q000494:pharmacology*; D006801:Humans; D051058:Oncogene Protein v-akt / Q000378:metabolism; D010936:Plant Extracts / Q000494:pharmacology
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D051017:Apoptosis Regulatory Proteins; D006576:Heterocyclic Compounds, 4 or More Rings; D010936:Plant Extracts; C575387:methyl 8-(3-furyl)-2a,4,5,5a,6,6a,8,9,9a,10a,10b,10c-dodecahydro-3-hydroxy-2a,5a,6a,7-tetramethyl-5-(3-methylbut-2-enoyloxy)-2H,3H-cyclopenta(4',5')furo(2',3'-6,5)benzo(cd)isobenzofuran-6-acetate; D051058:Oncogene Protein v-akt